IN

Incanthera plc

Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.

INC | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Incanthera plc is a therapeutics company specializing in the fields of dermatology and oncology. The company focuses on discovering and developing targeted solutions and transformative treatment technologies to address unmet medical needs. It leverages unique formulation and delivery technologies for its product pipeline. Incanthera's current commercial focus is its proprietary skincare brand, SKIN + CELL, which offers dermatological applications developed from its core technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 08:30
Pre-Annual General Meeting Information
AGM 2025 Update
English 16.0 KB
2025-10-16 11:15
Investor Presentation
Proactive Investor Forum Presentation
English 18.0 KB
2025-10-14 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 20.7 KB
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Incanthera plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea 086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
BIO-TECHNE Corp Logo
Develops reagents and instruments for life sciences research and clinical diagnostic markets.
United States of America TECH
biote Corp. Logo
Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.
United States of America BTMD
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland BIOV

Talk to a Data Expert

Have a question? We'll get back to you promptly.